TrialFrontiers in immunology2025

Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.

Masaya Fujitani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.